Drug Search Results
More Filters [+]

Edaglitazone

Alternative Names: edaglitazone
Latest Update: 2023-04-28
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: N/A

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Edaglitazone

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BM17151

P2

Completed

Type 2 Diabetes

2004-03-01

Recent News Events

Date

Type

Title